Bryn Pharma, a privately held pharmaceutical company focused on creating a new treatment for anaphylaxis - a life-threatening allergic reaction - not only has a new CEO and COO but also $15 million in cash as the company seeks FDA approval for its unique nasal spray.
Data presented at the American Society for Clinical Pharmacology and Therapeutics annual meeting show promise for Utuly, a novel intranasal epinephrine spray for treating anaphylaxis.
Bryn Pharma has appointed a new Chief Operating Officer, the company announced this week. This announcement comes just two weeks after the Raleigh-based startup named a new CEO.
RALEIGH, N.C. (BUSINESS WIRE) #anaphylaxis Bryn Pharma LLC, a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, announced today that pharmaceutical industry veteran Sandy Loreaux has been appointed CEO, effective immediately. David Dworaczyk,.